Prevalence of metabolic syndrome in women with polycystic ovary syndrome

Panidis, Dimitrios; Macut, Djuro; Τζιόμαλος, Κωνσταντίνος; Papadakis, Efstathios; Mikhailidis, Konstantinos; Kandaraki, Eleni; Tsourdi, Elena; Tantanasis, T; Mavromatidis, Georgios; Katsikis, Ilias

doi:10.1111/cen.12008

Cited by 58 publications

(47 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9,10,[25][26][27] Prevalence of the MetS using three criteria within our PCOS women was in the range of 16.2 to 19.4% and is similar to the prevalence in other Europid populations. 10,26,28 There is a universally established relationship obesity and the MetS. The prevalence of obesity is rising worldwide and is considered to be contributing directly to the current high prevalence of the MetS.…”

Section: Discussionsupporting

confidence: 79%

“…[8][9][10] Although excessive weight predominates among PCOS women assessed for the presence of MetS, it is assumed that PCOS women have an increased risk for the metabolic syndrome that is independent of insulin resistance or obesity. 10,11 As the diagnosis of MetS is established from the combination of anthropometric and laboratory measures, there is a need for the simplest and the most accurate method of assessment of risk factors to which PCOS women are exposed during the long period of transition from subclinical to overt cardiovascular disease. 12 Therefore, lipid accumulation product (LAP) was proposed in an attempt to develop an easy predictor of cardiovascular disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome

Macut¹,

Antić²,

Bjekić-Macut³

et al. 2015

Self Cite

View full text Add to dashboard Cite

oBJectIVe: there is a need for a simple and accurate method for the assessment of cardiovascular risk in polycystic ovary syndrome (Pcos). Lipid accumulation product (LAP) is based on the assessment of waist circumference and serum triglycerides that yield an estimation of lipid overaccumulation. we aimed to determine whether LAP is associated with metabolic syndrome (Mets) in caucasian women with Pcos. desIGn: we studied 222 women with Pcos who were diagnosed using the Rotterdam criteria. In all the subjects and controls, LAP was determined and the Mets was assessed using three different international criteria, nceP-AtP III, Idf, and JIs. Roc curve and logistic regression analyses were performed to determine and analyze associations with the Mets. ResuLts: In the study population the prevalence of Mets was 16.2-19.4%. the cut-off value of 25.9 determined that LAP has the strongest association with Mets whichever international criteria are used, followed by HdL (nceP-AtP III and JIs) and glucose (Idf). concLusIons: LAP is used as an independent clinical indicator for Mets in our Pcos women of caucasian origin. the high diagnostic accuracy of LAP is superseding the need for the use of multiple clinical indicators for the assessment of lipid accumulation as a prerequisite for diagnosis of metabolic and cardiovascular diseases in Pcos women.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome

Macut¹,

Antić²,

Bjekić-Macut³

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Usually, women with classic PCOS are characterised by higher body weight, but when comparisons were made between groups matched for age and BMI, it was obvious that the degree of dyslipidaemia, central adiposity, insulin resistance and metabolic syndrome prevalence was significantly higher in women with the classic (or more severe) PCOS phenotype. The prevalence of metabolic syndrome and degree of insulin resistance in the milder phenotype (oligo-anovulatory patients with PCOm but without hyperandogenaemia), although elevated (28), are closer to control subjects than to the other three phenotypes (29). Specifically, women with this phenotype usually display normal insulin sensitivity and a metabolic profile similar to ageand BMI-matched normal women.…”

Section: The Debate On the Definition Of Pcosmentioning

confidence: 90%

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

Conway¹,

Dewailly²,

Diamanti-Kandarakis³

et al. 2014

European Journal of Endocrinology

Self Cite

568

492

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common ovarian disorder associated with androgen excess in women, which justifies the growing interest of endocrinologists. Great efforts have been made in the last 2 decades to define the syndrome. The presence of three different definitions for the diagnosis of PCOS reflects the phenotypic heterogeneity of the syndrome. Major criteria are required for the diagnosis, which in turn identifies different phenotypes according to the combination of different criteria. In addition, the relevant impact of metabolic issues, specifically insulin resistance and obesity, on the pathogenesis of PCOS, and the susceptibility to develop earlier than expected glucose intolerance states, including type 2 diabetes, has supported the notion that these aspects should be considered when defining the PCOS phenotype and planning potential therapeutic strategies in an affected subject. This paper offers a critical endocrine and European perspective on the debate on the definition of PCOS and summarises all major aspects related to aetiological factors, including early life events, potentially involved in the development of the disorder. Diagnostic tools of PCOS are also discussed, with emphasis on the laboratory evaluation of androgens and other potential biomarkers of ovarian and metabolic dysfunctions. We have also paid specific attention to the role of obesity, sleep disorders and neuropsychological aspects of PCOS and on the relevant pathogenetic aspects of cardiovascular risk factors. In addition, we have discussed how to target treatment choices based according to the phenotype and individual patient's needs. Finally, we have suggested potential areas of translational and clinical research for the future with specific emphasis on hormonal and metabolic aspects of PCOS.

show abstract

“…При дальнейшем сравнении подгрупп по возрастам риск МС у пациенток с СПКЯ был выше во всех возрастных подгруппах (p<0,001). Следует от-метить, что крупное когортное исследование с уча-стием 1223 пациенток с СПКЯ и 277 здоровых паци-енток показало, что при сопоставлении групп жен-щин по ИМТ частота встречаемости МС была сход-ной для женщин с СПКЯ и женщин контрольной группы при использовании 3 из 4 определений МС (МС встречался несколько чаще у женщин с СПКЯ при использовании определения NCEP ATP III) [10]. Хотя частота МС была выше среди женщин с СПКЯ, различие в первую очередь было обусловлено более высокими значениями ИМТ у последних.…”

Section: мс и репродуктивные нарушенияunclassified

Metabolic syndrome and female reproductive system (review)

Dyakonov¹

2016

Probl. reprod.

View full text Add to dashboard Cite

Метаболический синдром (МС) является одной из наиболее частых причин ановуляторного беспло-дия, ранних потерь беременности у женщин репро-дуктивного возраста. Частота данной патологии со-ставляет около 30-35% в структуре нарушений ре-продуктивной функции и достигает 70% среди паци-енток с рецидивирующими гиперпластическими процессами эндометрия. Таким образом, МС явля-ется одним из самых распространенных заболеваний молодых женщин [1]. Избыточное содержание в ор-ганизме жировой ткани сопровождается метаболи-ческими, гормональными, сосудистыми и провоспа-лительными нарушениями [2], вследствие чего, це-лесообразным представляется рассмотреть суще-ствующие представления о взаимодействиях между МС, ожирением и репродуктивной системой жен-щин.Определения метаболического синдрома МС рассматривается как комбинация наруше-ний, комплекс которых ассоциируется с повышени-ем риска развития сердечно-сосудистых заболева-ний и сахарного диабета [3]. В настоящее время спе-циалистами используется несколько определений МС. metabolic syndrome (ms) is one of the most common causes of anovulatory infertility and early pregnancy loss in women of reproductive age. this review is dedicated to existing concepts of interactions between metabolic syndrome, obesity and female reproductive system.

show abstract

Prevalence of metabolic syndrome in women with polycystic ovary syndrome

Abstract: Polycystic ovary syndrome per se does not appear to increase the risk of MetS independent of abdominal obesity.

Cited by 58 publications

References 38 publications

Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome

Lipid accumulation product is associated with metabolic syndrome in women with polycystic ovary syndrome

The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

Metabolic syndrome and female reproductive system (review)

Contact Info

Product

Resources

About